ACADIA Pharmaceuticals Revenue 2006-2021 | ACAD

ACADIA Pharmaceuticals revenue from 2006 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
ACADIA Pharmaceuticals Annual Revenue
(Millions of US $)
2020 $442
2019 $339
2018 $224
2017 $125
2016 $17
2015 $0
2014 $0
2013 $1
2012 $5
2011 $2
2010 $42
2009 $6
2008 $2
2007 $8
2006 $8
2005 $11
ACADIA Pharmaceuticals Quarterly Revenue
(Millions of US $)
2021-06-30 $115
2021-03-31 $107
2020-12-31 $121
2020-09-30 $121
2020-06-30 $110
2020-03-31 $90
2019-12-31 $98
2019-09-30 $95
2019-06-30 $83
2019-03-31 $63
2018-12-31 $60
2018-09-30 $58
2018-06-30 $57
2018-03-31 $49
2017-12-31 $44
2017-09-30 $36
2017-06-30 $30
2017-03-31 $15
2016-12-31 $12
2016-09-30 $5
2016-06-30 $0
2016-03-31 $0
2015-12-31 $0
2015-09-30 $0
2015-06-30 $0
2015-03-31 $0
2014-12-31 $0
2014-09-30 $0
2014-06-30 $0
2014-03-31 $0
2013-12-31 $0
2013-09-30 $0
2013-06-30 $0
2013-03-31 $0
2012-12-31 $0
2012-09-30 $3
2012-06-30 $1
2012-03-31 $0
2011-12-31 $1
2011-09-30 $1
2011-06-30 $0
2011-03-31 $0
2010-12-31 $35
2010-09-30 $2
2010-06-30 $2
2010-03-31 $2
2009-12-31 $2
2009-09-30 $2
2009-06-30 $2
2009-03-31 $0
2008-12-31 $0
2008-09-30 $0
2008-06-30 $0
2008-03-31 $1
2007-12-31 $2
2007-09-30 $2
2007-06-30 $2
2007-03-31 $2
2006-12-31 $2
2006-09-30 $2
2006-06-30 $2
2006-03-31 $3
2005-12-31 $2
2005-09-30 $4
2005-06-30 $3
2005-03-31 $2
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.813B $0.442B
Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00